Pancreatic stone protein (PSP) has significant potential as ‘early marker’ for sepsis detection

Abionic device

TRUE ENABLER OF EARLY SEPSIS DETECTION SEE EARLIER - ACT FASTER

PSP (pancreatic stone protein) on the abioscope, True enabler of early sepsis detection.

Pancreatic Stone Protein (PSP) is the Earliest Marker of Sepsis.

Early Sepsis Detection Up To 72 Hours Before the Standard of Care In 5 Min.

1.Description:

The IVD capsule PSP on the abioscope is the first CE-marked in vitro diagnostic test to enable fast, reliable and early sepsis detection at the point-of-care from a single drop of blood in only 5 minutes.

A multicentric study published recently in Critical Care, proves that bedside measurement of PSP on the abioSCOPE clearly correlates with the onset of sepsis, enabling personalized clinical management of patients in the ICU3.

An increasing PSP concentration in the days preceding the clinical diagnosis of sepsis, offers a unique window of opportunity for clinicians to initiate timely the right treatment.

IVD capsule PSP on the abioscope designed for on-demand use in the ICU

Scope of Use for the PSP Biomarker in the Diagnosis of Sepsis in Adults

2.Technology:

UNIQUE NANOTECHNOLOGY-BASED PLATFORM

Abionic’s Patented Nanofluidic Immunoassay Revolutionizes Point-of-Care Diagnostics.

Abionic’s technology enables quantitative results for up to 14 specific parameters in a single capsule. Molecules are forced into a nanochannel, limiting their travel distance to a few hundred nanometres and reducing incubation time to 2 minutes. A washing step is not needed as the surface-to-volume ratio is extremely high, and non-specific background is negligible. PSP level can thus be efficiently quantified within an ultra-short assay time, with high precision and accuracy on a closed, small, easy-to-operate platform, providing lab quality results at the point-of-care.

3.Unique Benefits

First result within 5 minutes

The abioSCOPE® is the fastest point-of-care device in the world

Intuitive and easy to use

Abionic's technology is accessible and the test is painless for the patient

Universal platform

The abioSCOPE® is compatible with a wide range of applications

Patented technology

The abioSCOPE® process is based on a nanofluidic technology

Clinically validated

All analytical performances are clinically validated

One drop of blood

All our tests are run with just a few µL of whole blood sample

Sepsis is one of the leading causes of death in the world. It is a life-threatening condition caused by a dysregulated host response to infection. The pancreatic stone protein (PSP) is a host protein biomarker produced by the pancreas in response to a sepsis-related organ dysfunction and has shown a great potential in the early identification of septic patients. Abionic has succeeded in bringing together an ultra-rapid nanofluidic based diagnostic platform and the PSP biomarker to offer a unique simple bedside test for the earliest and immediate detection of sepsis.